Inactivation of expression of MGMT gene as an effect of MGMT promoter methylation has been found as a relevant predictive biomarker of the response to the alkylating drug temozolomide in patients affected by glioma (6) and the original observation was basically confirmed by several replication studies (28–84). The gene discussed is MGMT; the disease is central nervous system cancer.